AbbVie Inc Earnings - Q2 2026 Analysis & Highlights
AbbVie delivered strong Q2 2026 results with double-digit revenue growth, robust performance across its immunology and neuroscience portfolios, and strategic pipeline advancement highlighted by multiple regulatory approvals and the planned acquisition of Apogee Therapeutics to strengthen its immunology position.
Key Financial Results
Total net revenues of nearly $17 billion, reflecting robust sales growth of 10.2% and beating expectations by $300 million.
Adjusted earnings per share of $3.65, which is $0.06 above guidance midpoint.
Adjusted gross margin of 84.7% of sales, with adjusted R&D expense at 13.6% of sales and adjusted SG&A expense at 21% of sales.
Adjusted operating margin of 48.3% of sales, which includes a 1.7% unfavorable impact from acquired IPR&D expense.
Net interest expense of $679 million and adjusted tax rate of 14.7%.
Business Segment Results
Immunology revenues of nearly $8.8 billion, reflecting very strong operational sales growth of 14.6%.
Skyrizi total sales of $5.5 billion, up 24% on an operational basis, with market share leadership now in more than 30 countries.
Rinvoq global sales of more than $2.5 billion, up 23.7% on an operational basis, with particularly strong momentum in gastroenterology on pace to deliver 30% global sales growth this year.
Humira global sales of $756 million, down 36.1% on an operational basis, reflecting biosimilar competition and in line with expectations.
Neuroscience total revenues of more than $3.2 billion, up approximately 20% on an operational basis.
Vraylar global sales of nearly $1.1 billion, up approximately 19%, reflecting share gains in both bipolar disorder and adjunctive MDD.
Botox Therapeutic, Ubrelvy and Qulipta each delivering double-digit sales growth in the migraine portfolio.
Vyalev sales of $256 million, up more than 27% on a sequential basis, well on track to achieve blockbuster sales this year.
Oncology total revenues of more than $1.6 billion, down 2.4% on an operational basis.
Venclexta total sales of $771 million, up 9.6% on an operational basis.
Aesthetics global sales of nearly $1.3 billion, down 0.9% on an operational basis.
Botox Cosmetic total revenues of $728 million, up 3.4% operationally.
Juvederm global sales of $245 million, down 6.6% operationally.
Capital Allocation
Planned acquisition of Apogee Therapeutics announced during the quarter, adding multiple differentiated assets in dermatology, respiratory, and other related inflammatory diseases.
Interim financing secured for the Apogee transaction with expectation to issue long-term debt in the coming months.
Commitment to achieve a net leverage ratio of 2 times within two to three years following the Apogee deal close.
Substantial financial flexibility to pursue additional innovative business development based on strong cash flows, balance sheet, and business outlook.
Industry Trends and Dynamics
IL-23 category seeing very robust growth in both Crohn's disease and ulcerative colitis, with competitive dynamics remaining in line with expectations.
Immunology markets described as amazingly resilient and very expansive once new technologies come in, with these being lifelong conditions allowing for multiple lines of therapy.
Vitiligo market emerging as a new systemic treatment opportunity with no systemic treatments currently approved, representing significant market expansion potential.
Psoriasis market showing significant headroom with a large percentage of patients in the United States and around the world still not on advanced therapy.
Dermal filler markets experiencing continued headwinds globally.
Competitive Landscape
Skyrizi capturing robust in-play share of new and switching patients at a rate 4 times higher than any other biologic or oral treatment in the US for psoriasis.
Skyrizi demonstrating superior efficacy in head-to-head trials versus five different mechanisms, including both biologics and oral agents.
No material impact expected to robust psoriasis outlook from existing or new therapies given Skyrizi's very distinct profile.
Icotyde launch not materially impacting Skyrizi momentum, with vast majority of Icotyde's share sourced from other oral competitors and no degradation in Skyrizi NBRx trends observed since Icotyde's March launch.
Skyrizi capturing leading share of total new patient starts in IBD in the US, including substantial leadership in the frontline setting.
Rinvoq competitively positioned for vitiligo and alopecia areata with expanded US dermatology field force to support launches.
Temab-A demonstrating strong anti-tumor activity with response rates reaching as high as 80% in platinum-resistant ovarian cancer in c-Met selected patients.
Temab-A showing 50% response rate in clear cell carcinoma, a segment with high unmet need that typically does not respond well to cytotoxic therapy.
Macroeconomic Environment
Foreign exchange providing 0.7% favorable impact on Q2 net revenues.
Full-year foreign exchange assumptions revised to reflect roughly 0.5% favorable impact on full-year sales growth, reflecting less benefit than previous expectation.
Q3 foreign exchange estimated at 0.4% unfavorable impact.
Growth Opportunities and Strategies
Skyrizi subcutaneous induction dosing for Crohn's disease supported by very strong data, particularly in the frontline where highest levels of endoscopic response were observed in the category.
Subcutaneous induction regimen demonstrating very high levels of endoscopic response and clinical remission, with rates 25 points higher than placebo in overall population and 45 points higher in patients naive to advanced therapy.
Phase 2b combination trial in IBD evaluating Skyrizi plus higher dose of novel anti-alpha-4 beta-7 antibody and extended half-life TL1A antibody in both Crohn's disease and ulcerative colitis.
Interim results for Skyrizi plus anti-alpha-4 beta-7 in Crohn's disease demonstrating doubling of endoscopic remission at week-24 compared to either monotherapy.
Phase 3 programs in IBD anticipated to kick-off in first half of 2028 based on interim data from Phase 2b combination trial.
Rinvoq approved in Europe for severe alopecia and non-segmental vitiligo, with US approval decisions anticipated later this year for vitiligo and early next year for alopecia areata.
Combined peak sales for Rinvoq vitiligo and alopecia areata indications anticipated to approach $2 billion, meaningfully above prior expectations.
Qulipta now approved in Europe for acute treatment of migraine, expanding options for patients.
Qulipta approved in Europe for both acute treatment and once-daily preventative treatment for chronic or episodic migraine.
Oral CGRPs collectively expected to achieve more than $5 billion of peak sales.
FDA approval decision expected in third quarter for tavapadon, a novel selective D1/D5 dopamine agonist for Parkinson's disease.
Tavapadon demonstrating strong efficacy as both monotherapy and add-on to standard of care, with more than 90%-plus of patients not needing to increase levodopa-carbidopa dose after 85 weeks.
Parkinson's portfolio with Vyalev, tavapadon and Duopa expected to achieve collective peak sales of more than $5 billion.
Decnupaz approved by FDA for blastic plasmacytoid dendritic cell neoplasm, representing AbbVie's first marketed ADC in hematology.
Boey approved in Europe and Canada as a rapid onset and short duration toxin for temporary improvement in appearance of glabellar lines.
Boey expected to meaningfully expand the toxin market and represent a new way for patients to initiate aesthetic treatment.
Temab-A granted Breakthrough Therapy Designation in combination with bevacizumab in refractory metastatic colorectal cancer.
Phase 3 strategy for Temab-A in all-comer third-line plus colorectal cancer setting with trial actively recruiting.
Phase 2 study data expected later this year evaluating Temab-A combinations versus chemotherapy in second-line colorectal cancer.
Temab-A Phase 2 study evaluating combination with pembrolizumab in frontline head and neck cancer to start soon.
Phase 2 study evaluating Temab-A with FOLFOX as frontline combination therapy in pancreatic cancer recently initiated.
Interim analysis planned in third quarter for progression-free survival from etentamig monotherapy third-line plus trial in multiple myeloma.
Phase 3 study evaluating etentamig in combination with pomalidomide in second-line plus patients to begin by year-end.
Encouraging early-stage results for etentamig in relapsed/refractory light chain amyloidosis with 100% of patients achieving hematologic complete response at 40-milligram dose.
Phase 3 trial in newly diagnosed light chain amyloidosis patients being planned based on etentamig results.
Three early-stage dermatology programs recently advanced into clinic, including IL-13/IL-31 receptor bispecific antibody for atopic dermatitis, oral IL-23 receptor inhibitor for psoriasis, and long-acting IL-1 alpha/beta bispecific antibody for Hidradenitis Suppurativa.
Rinvoq and lutikizumab Phase 3 trials in Hidradenitis Suppurativa on track for 16-week data later this year.
Phase 2 study for novel toxin GemibotA in essential tremor recently initiated.
Phase 1b study for ABBV-1758, a blood-brain barrier crossing anti-pyroglutamate a-beta antibody in Alzheimer's disease, recently initiated.
ABBV-1758 demonstrating extended half-life and better cerebrospinal fluid penetration than naked antibody, with transport working as designed.
ABBV-1758 potentially set up for subcutaneous monthly dosing to provide simplicity in patient experience.
Multi-ascending dose study for emraclidine in schizophrenia nearing completion, with 100-milligram dose retaining safe and tolerable profile and 150 milligrams being evaluated.
Dose selection for emraclidine in both schizophrenia and psychosis programs expected in coming months, with Phase 2 studies anticipated to begin in fourth quarter.
Apogee acquisition adding portfolio of long-acting biologics targeting atopic dermatitis, respiratory conditions and other immune-mediated diseases.
Apogee assets highly complementary to immunology strategy and further strengthening robust pipeline.
Ample financial capacity for more business development with focus on adding both early- and late-stage opportunities across core disease areas.
Pipeline and Regulatory Progress
US approval of Decnupaz for rare form of blood cancer.
European approvals for Qulipta to treat acute migraine.
European approvals for Epkinly for second-line follicular lymphoma.
European approvals for Boey, a first-in-class short-acting toxin in aesthetics.
European approvals for Rinvoq in vitiligo and alopecia areata, with US regulatory decisions forthcoming.
US application for Skyrizi's subcutaneous induction in Crohn's disease under review, with approval decision expected later this fall.
Full results from Skyrizi subcutaneous induction study expected to be presented this fall, including additional important endpoints such as endoscopic remission.
Financial Guidance and Outlook
Full year adjusted earnings per share guidance updated to between $13.87 and $14.07.
Update reflects $0.10 improvement in outlook of existing business based on strong second quarter results and continued momentum.
Guidance now includes $0.14 of anticipated dilution related to planned Apogee acquisition.
Total net revenues expected at approximately $67.6 billion, an increase of $300 million.
Skyrizi global revenues expected at $21.7 billion, an increase of $100 million based on momentum across psoriatic and IBD indications.
Total neuroscience revenues expected at $12.7 billion, an increase of $100 million, with Vraylar sales approaching $4.1 billion and Botox Therapeutic sales approaching $4.2 billion.
Remaining $100 million increase reflects momentum from Rinvoq and Venclexta.
Full year adjusted gross margin expected above 84% of sales.
Adjusted R&D expense expected at approximately $9.8 billion, an increase of $100 million, reflecting Apogee-related pipeline investments.
Adjusted SG&A expense expected at approximately $14.5 billion.
Adjusted operating margin ratio anticipated to approach 47% of sales.
Adjusted net interest expense expected at approximately $2.9 billion, an increase of $200 million, reflecting partial year financing cost of planned Apogee transaction.
Non-GAAP tax rate forecasted at approximately 14.5%, reflecting impact of acquired IPR&D.
Q3 net revenues anticipated at approximately $17.2 billion, including estimated 0.4% unfavorable impact from foreign exchange.
Q3 adjusted earnings per share forecast between $3.84 and $3.88.
Q3 guidance contemplates partial quarter of dilution related to planned Apogee transaction.
Apogee transaction expected to close in third quarter.
Revenue guidance does not include estimate for acquired IPR&D expense that may be incurred beyond second quarter.
Q3 guidance does not include acquired IPR&D expense that may be incurred in the quarter.
Full-year revenue guidance raised by $300 million, with total revenue raised by $600 million since start of year.
